Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms

Noam E Kopmar¹, Ted Gooley², Niall Curley¹, Kathryn Russell¹, Carole Shaw³, Kelda Schonhoff¹, John Lim¹, Anna B Halpern^{1

3}, Roland B Walter^{1

3

4

5}, Bart L Scott^{1

3}, Jacob Appelbaum¹, Paul C Hendrie¹, Elihu H Estey^{1

3}, Mary-Elizabeth M Percival^{1

3}

Affiliations

¹ Department of Medicine, University of Washington, Seattle, WA, USA.
² Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
³ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
⁴ Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA.
⁵ Department of Epidemiology, University of Washington, Seattle, WA, USA.

Clinical Trial

Noam E Kopmar et al. Leuk Lymphoma. 2023 May.

. 2023 May;64(5):1057-1059.

doi: 10.1080/10428194.2023.2185087. Epub 2023 Mar 9.

¹ Department of Medicine, University of Washington, Seattle, WA, USA.
² Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
³ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
⁴ Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA.
⁵ Department of Epidemiology, University of Washington, Seattle, WA, USA.

No abstract available

Figures

1. Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80(2):115–26. - PubMed
1. Halpern AB, Othus M, Huebner EM, et al. Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. Haematologica. 2019;104(4):e143–e146. - PMC - PubMed
1. Skipper HE, Perry S. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res. Jun 1970;30(6):1883–97. - PubMed
1. Plunkett W, Liliemark JO, Adams TM, et al. Saturation of 1-beta-D-arabinofuranosylcytosine 5’-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. Jun 01 1987;47(11):3005–11. - PubMed
1. Garcia-Manero G, Othus M, Pagel JM, Radich J, Fang M. SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). Blood. 2016;128(22): 901.